Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
This study is currently recruiting participants.
Verified September 2012 by VU University Medical Center
Study NCT01462214   Information provided by VU University Medical Center

First Received on October 10, 2011.   Last Updated on September 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Renal Cell Cancer
Additional conditions recognized in this trial
Carcinoma, Renal Cell
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
Everolimus
Additional drug interventions recognized in this trial
Cyclophosphamide
Sirolimus
More general drug interventions related to this trial
Alkylating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Hans J. van der Vliet, MD, PhD
Dutch Cancer Society
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services